Our first domain. Biotech startups run on proprietary data, protein sequences, compound libraries, and clinical datasets. Opos filters sensitive data locally before anything reaches external APIs, presents the full plan before executing, and logs every model call with a complete audit trail. Scientists describe what they need in plain language. Opos handles the rest.
AI Models Orchestrated
BioNeMo
NVIDIA
Protein structure prediction, molecular docking, drug compound analysis.
AlphaFold 3
Google DeepMind
Protein structure and molecular interaction prediction.
ESM3
Meta
Protein language model for sequence and function analysis.
Chai Discovery
Partnered with Pfizer
Small molecule drug discovery and compound screening.
Boltz
Partnered with GSK
Biologics design and antibody engineering.
Noetik
Foundation Models
Cancer clinical outcome prediction and patient stratification.
→
Screen 50,000 compounds against a target protein, Opos selects BioNeMo for docking, Claude for report synthesis, filters all proprietary structures locally.
→
Predict protein-drug interactions across a compound library, AlphaFold 3 handles structure, ESM3 handles sequence context, full audit trail generated.
→
Generate investor-ready pipeline reports from raw lab data, every model choice justified before execution, every data path logged.